A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 2, 2015, Pages 214-221

  Fonte, C ^a   Fatigoni, S ^a   Roila, F ^a  

^a S MARIA HOSPITAL   (Italy)

Author keywords

Breakthrough emesis; Chemotherapy induced emesis; Emesis in terminal cancer patients; Olanzapine

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; AZASETRON; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANISETRON; IRINOTECAN; METOCLOPRAMIDE; OLANZAPINE; ONDANSETRON; PALONOSETRON; PLACEBO; PROCHLORPERAZINE; RAMOSETRON; BENZODIAZEPINE DERIVATIVE;

ABNORMAL VISION; AKATHISIA; AMBLYOPIA; ANTIEMETIC ACTIVITY; ATRIAL FIBRILLATION; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONSCIOUSNESS DISORDER; DELUSION; DEPRESSION; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EUPHORIA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LEUKEMIA; LOSS OF APPETITE; MANIA; MOOD CHANGE; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PNEUMONIA; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SLEEP DISORDER; SOMNOLENCE; SUICIDE ATTEMPT; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; WEIGHT GAIN; XEROSTOMIA; CHEMICALLY INDUCED; METABOLISM; NAUSEA; PALLIATIVE THERAPY; PROCEDURES; VOMITING;

ANTIEMETICS; BENZODIAZEPINES; HUMANS; NAUSEA; PALLIATIVE CARE; VOMITING;

EID: 84937513550     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.02.010     Document Type: Review

References (42)

1. Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21(Suppl. 5):232-243.
2. Basch E., Prestrud A.A., Hesketh P.J., et al. Antiemetic American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011, 29:4189-4198.
3. Davis M.P., Hallerberg G. A systematic review of the treatment of nausea and vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage 2010, 39:756-767.
4. Bruera E., Belzile M., Neumann C., et al. A double-blind, crossover study of the controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000, 19:427-435.
5. Gupta M., Davis M., LeGrand S., et al. Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol. J Support Oncol 2013, 11:8-13.
6. European Medicines Agency recommends changes to the use of metoclopramide. Change aim mainly to reduce the risk of neurological side effects. 26 July 2013, EMA/443003/2013.
7. Smith H.S., Laufer A. Opioid induced nausea and vomiting. Eur J Pharmacol 2014, 722:67-78.
8. Hardy J., Daly S., McQuade B., et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24mg p.o. with placebo and metoclopramide 10mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer 2002, 10:231-236.
9. Bymaster F.P., Calligaro D., Falcone J., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
10. Stephenson C.M.E., Pilowsky L.S. Psychopharmacology of olanzapine: a review. Br J Psychiatry 1999, 174:52-58.
11. Bymaster F.P., Falcone J.F., Bauzon D., et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 2001, 430:341-349.
12. Passik S., Lundberg J., Kirsh K.L., et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002, 23:526-532.
13. Brafford M.V., Glode A. Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol 2014, 5:24-29.
14. Pirl W.F., Roth A.J. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 2000, 9:84-87.
15. Passik S.D., Kirsh K.L., Theobald D.E., et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003, 25:485-489.
16. Passik S.D., Navari R.M., Jung S.H., et al. A phase I trial of olanzapine for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004, 22:383-388.
17. Navari R.M., Einhorn L.H., Passik S.D., et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005, 13:529-534.
18. Navari R.M., Einhorn L.H., Loehrer P.J., et al. A phase II trial of olanzapine, dexamethasone and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2007, 15:1285-1291.
19. Tan L., Liu J., Liu X., et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009, 28:1-7.
20. Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011, 9:188-195.
21. Cleeland C.S., Mendoza T.R., Wang X.S., et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 1999, 94:1011-1015.
22. Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Clin Oncol 2010, 28:641s. [abstract 9020].
23. Shumway N.M., Terrazzino S.E., Jones C.B. A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. J Clin Oncol 2009, 27:516s. [abstract 9633].
24. Mizukami N., Yamauchi M., Koike K., et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo controlled study. J Pain Symptom Manage 2014, 47:542-550.
25. Chanthawong S., Subongkot S., Sookpraseert A. Evaluation of olanzapine for breakthrough emesis in patients with cancer not responding to standard antiemetic regimen. J Clin Oncol 2011, 29. [abstract e19596].
26. Navari R.M., Nagy C.K., Gray S.E. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013, 21:1655-1663.
27. Roth B.J., Krilov L., Adams S., et al. Clinical cancer advances 2012: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2013, 31:131-161.
28. Navari R.M., Gray S. Treatment of chemotherapy-induced breakthrough nausea and vomiting. 7th annual conference of the American Psychosocial Oncology Society 2010.
29. Navari R.M., Gray R.E. Treatment of chemotherapy-induced breakthrough nausea and vomiting. J Clin Oncol 2009, 27:e20536.
30. Jackson W.C., Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med 2003, 6:251-255.
31. Srivastava M., Brito-Dellan N., Davis M.P., et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003, 25:578-582.
32. Lundberg J.C., Passik S. Controlling opioid-induced nausea with olanzapine. Primary Care Cancer 2000, 20:35-37.
33. Atkinson S.R. Olanzapine for intractable nausea and vomiting in palliative care patients not receiving chemotherapy. J Palliat Med 2014, 17:503-504.
34. Suzuki M., Komuro K., Ohara K. Olanzapine and betamethasone are effective for the treatment of nausea and vomiting due to metastatic brain tumors of rectal cancer. Case Rep Gastroenterol 2014, 8:13-17.
35. Passik S.D., Lundberg J., Kirsh K.L., et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002, 23:526-532.
36. Kaneishi K., Kawabata M., Morita T., et al. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage 2012, 44:604-607.
37. Hale A.S. Olanzapine. Br J Hosp Med 1997, 58:443-445.
38. Allison D.B., Casey D.F. Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 2001, 62:22-31.
39. Goldstein L.E., Sporn J., Brown S., et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999, 40:438-443.
40. Mahendran R., Liew E., Subramaniam M., et al. De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J Clin Psychiatry 2007, 68:542-545.
41. Hocking C.M., Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 2014, 22:1143-1151.
42. Belgamwar R.B., Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev 2005, 2:CD003729.